3 Promising Penny Stocks With Over $50M Market Cap

Over the last 7 days, the U.S. market has dropped 1.5%, but it has risen by 18% over the past year, with earnings forecasted to grow by 17% annually. For investors willing to explore beyond established names, penny stocks—often smaller or newer companies—can present intriguing opportunities despite their somewhat outdated label. By focusing on those with strong financials and a clear growth path, investors can discover promising options that balance potential upside with stability.

Underneath we present a selection of stocks filtered out by our screen.

Sensus Healthcare (SRTS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Sensus Healthcare, Inc. is a medical device company that manufactures and sells radiation therapy devices to healthcare providers globally, with a market cap of $54.98 million.

Operations: The company generates revenue from its Medical Laser Systems segment, which amounted to $17.51 million.

Market Cap: $54.98M

Sensus Healthcare, Inc., a medical device company with a market cap of US$54.98 million, faces challenges typical of penny stocks. Recent earnings show a decline in sales to US$2.29 million for Q2 2026 from US$7.32 million the previous year, alongside an increased net loss of US$8.75 million compared to US$1.04 million last year. Despite being debt-free and having short-term assets exceeding liabilities, Sensus remains unprofitable with losses growing over five years at 48.8% annually. The management team and board are experienced, but profitability remains elusive as revenue is forecasted to grow significantly by 29.37% per year.

• Unlock comprehensive insights into our analysis of Sensus Healthcare stock in this financial health report.
• Review our growth performance report to gain insights into Sensus Healthcare's future.

MediciNova (MNOV)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: MediciNova, Inc. is a biopharmaceutical company that develops novel and small molecule therapeutics for serious diseases with unmet medical needs in the United States, with a market cap of $68.42 million.

Operations: The company's revenue is derived entirely from the acquisition and development of small molecule therapeutics, totaling $0.92 million.

Market Cap: $68.42M

MediciNova, Inc., a biopharmaceutical firm with a market cap of US$68.42 million, remains pre-revenue with earnings of just US$0.92 million. Recent announcements highlight progress in clinical trials for MN-166 (ibudilast) targeting ALS and other neurodegenerative diseases, supported by NIH funding and FDA Fast Track Designation. Despite being debt-free and having sufficient cash runway for over two years, the company is unprofitable but has reduced losses over recent years. The seasoned management team continues to drive research initiatives while maintaining stability in short-term assets exceeding liabilities without significant shareholder dilution recently.

• Jump into the full analysis health report here for a deeper understanding of MediciNova.
• Gain insights into MediciNova's outlook and expected performance with our report on the company's earnings estimates.

Protalix BioTherapeutics (PLX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on developing, producing, and commercializing recombinant therapeutic proteins using its ProCellEx plant cell-based protein expression system, with a market cap of $191.76 million.

Operations: Protalix BioTherapeutics generates $80.62 million in revenue from its biotechnology startup segment.

Market Cap: $191.76M

Protalix BioTherapeutics, with a market cap of US$191.76 million, demonstrates strong financial health and growth potential in the biotech sector. The company has achieved profitability over the past five years, with earnings growing by 54.5% annually and a recent surge of 201.9% in the past year alone. It reported Q2 2026 revenue of US$19.9 million, up from US$15.66 million a year ago, and net income rose significantly to US$3.78 million from US$0.164 million previously. Protalix remains debt-free with robust short-term assets exceeding liabilities and no significant shareholder dilution recently observed.

• Click to explore a detailed breakdown of our findings in Protalix BioTherapeutics' financial health report.
• Explore Protalix BioTherapeutics' analyst forecasts in our growth report.

Next Steps

• Take a closer look at our US Penny Stocks list of 314 companies by clicking here.
• Looking For Alternative Opportunities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com